GenoLogics is a genomics LIMS software company servicing the life sciences market. The company’s flagship product, the GenoLogics LIMS, was designed specifically to meet the unique challenges of the next-generation genomics laboratory. Today, GenoLogics is well positioned to meet the future information management needs of the next-generation genomics lab with a LIMS that delivers a useable, scalable and adaptable solution to the biological research market.
The company has forged strong partnerships and customer relationships with leading academic institutions, research institutes, and sequencing instrumentation companies worldwide. GenoLogics’ customers include University of Washington, University of Southern California, the National Cancer Institute, Jackson Laboratory, Queensland Center for Medical Genomics, Pfizer, Sanofi Aventis, Stanford University, and EdgeBio.
GenoLogics has also developed strategic partnerships within the genomics industry, enabling it to better understand customer demands and to closely integrate its technology with leading instrumentation platforms. Its key instrument partners are Illumina and Life Technologies.
GenoLogics is headquartered in Victoria, BC Canada with satellite offices in San Francisco, CA and London, UK.
News on GenoLogics Life Sciences Software Inc.
If you've spent anytime surfing the Workopolis or Monster.com job boards looking for your next job, you know that there are a lot of lame, uninspiring opportunities out there. Don't waste your... more
Victoria's GenoLogics, a developer of software for biologists and physicians, has raised $1 Million of equity financing out of a round that could be worth $1.5 million. This is in addition... more
The Canadian Financing Forum is next week in Vancouver and the final list of presenting companies is now online. Advanced E-commerce Research Systems, Inc. Aquavive Technologies Inc Axia... more
Victoria's Genologics quietly completed their 3rd round round of financing late last month adding another $5 Million which will be applied towards ongoing expansion plans. This latest round of... more